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Cannabinoid interactions with ion channels and receptors
Abeline Rose Watkins
Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada
ABSTRACT
Cannabidiol (CBD), the non-psychoactive component of Cannabis sativa, acts on a diverse
selection of membrane proteins with promising therapeutic potential in epilepsy and chronic
pain. One such protein is the voltage-gated sodium channel (Nav). CBD shows a lack of
specificity for sodium channels; however, the method of interaction is still unknown. In this
review, we will outline the studies that report reproducible results of CBD and other cannabi-
noids changing membrane channel function, with particular interest on Nav. Nav are implicated
in fatal forms of epilepsy and are also associated with chronic pain. This makes Nav potential
targets for CBD interaction since it has been reported to reduce pain and seizures. One potential
method of interaction that is of interest in this review is whether CBD affects channel function
by altering lipid bilayer properties, independent of any possible direct interaction with mem-
brane channels. CBD’s ability to interact with its targets is a novel and important discovery. This
discovery will not only prompt further research towards CBD’s characterization, but also pro-
motes the application of cannabinoids as potentially therapeutic compounds for diseases like
epilepsy and pain.
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Cannabis sativa, a plant known more commonly
as marijuana, has become widely popular due to its
induced psychological and euphoric states in an
individual who ingests or smokes the plant. More
interestingly, the cannabinoids that cause these
desired effects also have potential health applica-
tions which have been seen to improve a variety of
symptoms such as neuropathic pain, seizures,
social defects, brain damage from stroke, and
lung function in inflammatory lung disease [1–8].
The most popularly used compounds recreation-
ally and therapeutically, Cannabidiol (CBD) and
trans-Δ⁹-tetrahydrocannabinol (THC)(Figure 1),
are classified as phytocannabinoids since they
naturally occur from the Cannabis plant [9].
Living organisms also biologically synthesize their
own cannabinoids, called endocannabinoids,
which interact with the organism’s endocannabi-
noid system (ECS) [9]. The ECS regulates hor-
mones associated with reproductive functions
and stress, and are localized in the brain, endo-
crine system, and immune tissues [10]. To target
these functions, non-natural structural analogs of
endo- and phytocannabinoids, known as synthetic
cannabinoids, are produced in laboratories to
interact with and regulate the ECS [9].
The ECS includes two endogenous cannabi-
noid receptors, CB1 and CB2. The interactions
between cannabinoids and cannabinoid receptors
have been extensively studied [11,12], but here,
we focus on different interactions. Although pre-
valent thought held that cannabinoids bind exclu-
sively to CB1 and CB2, this has been proven to be
false by countless studies showing interactions
between cannabinoids and other membrane pro-
teins [13–18]. Whereas some cannabinoids still
interact with CB1 and CB2, they also interact
with a large range of targets including other
receptors, transporters, enzymes, cellular struc-
tures, membranes, and ion channels [19,20]. The
intent of this review is to focus on the last two
listed targets; cellular membranes and ion chan-
nels. To break it down further, the cannabinoid of
interest is CBD due to the lack of data surround-
ing its effects and the popular and widespread use
of the compound in modern day society. CBD is
also different from other cannabinoids due to
some unique effects it exhibits, such as is its
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inverse antagonism of CB2 when compared to
THC [21]. In this review, we outline the known
interactions of CBD and other cannabinoids on
molecular targets, particularly voltage-gated
sodium channels (Nav), and discuss potential
mechanisms of CBD besides the known interac-
tions with CB1 and CB2.
Discussion
Sodium channel interactions
Nav are ion conducting transmembrane proteins
that allow the passage of sodium ions (Na+) along
their electrochemical gradient [22]. Once channels
are activated by a depolarizing membrane potential,
sodium flows into the intracellular environment
due to a lower concentration of Na+ on the inside
of the cell vs. outside [22]. Within milliseconds of
channel opening, an inactivation gate closes and the
channel becomes impermeant, preventing further
flow of ions through the central pore [22].
A common theme in cannabinoid research on
Nav is the ability of the drug to induce channel
block, or in other words, inhibit Na+ current
[14,15]. 2-AG ether, an endocannabinoid, was
found to decrease peak Na+ current in frog para-
thyroid cells which do not express CB1 and CB2.
These data suggest that cannabinoids can interact
with more than just their respective receptors to
produce current changes in ion channels. Basal prop-
erties of the frog parathyroid cells were unaffected
when 50 μM of 2-AG ether was applied to the
extracellular environment of the cells; however,
a 36 ± 8% decrease of peak current at −24mV was
reported to be irreversible due to the channels’
inability to recover its initial peak current after
a saline solution washout [15]. WIN 55,212–2, an
aminoalkylindole derivative that acts on target pro-
teins in a similar way to THC and CBD, was also
tested on Nav and produced left shifts in the V1/2 of
activation by 11.7 ± 1.6 mV and the V1/2 of inacti-
vation by 17.5 ± 1.9 mV [15]. This shift in activa-
tion/inactivation resulted in the channel becoming
inactive at more negative potentials, rendering fewer
channels available to activate at the −24mV potential
recorded for peak current when exposed to the drug
vs its native peak current alone. Another study on
Nav found introducing various synthetic cannabi-
noids and endocannabinoids to the extracellular
environment to also inhibit current, but they did
not test CBD [14]. Both studies demonstrated that
cannabinoids affect Nav function with changes in
biophysical properties of activation/inactivation in
addition to the current block. With some insight
on how cannabinoids affect sodium channels,
research can move a step closer in determining
other cannabinoid interactions throughout the body.
Based on previous studies reporting Nav block
with drugs similar to CBD, a study of CBD effects
on Nav was done to determine whether CBD
directly or indirectly affects sodium channels
[20]. Interestingly, CBD had no specificity to any
of Nav1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, or mNav1.6
and also produced similar inhibitory effects with
~90% inhibition of sodium conduction in Nav1.3
when 3.3 µM CBD was applied [20]. When look-
ing for a mechanism of interaction, potency of
CBD was tested in a F1763A-mutant Nav channel
(altering the local anesthetic receptor site) to find
only a slight decrease in potency suggesting that
CBD does not inhibit at the classic pore-binding
sites for Nav1.1 [20]. This suggests that CBD may
interact through a mechanism that is common
Figure 1. Line drawing chemical structures of cannabidiol (CBD) and trans-Δ⁹-tetrahydrocannabinol (THC)
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among an array of different channels such as
fenestrations, or by changes to the membrane
environment in which channels are situated.
Other channel interactions
In support of cannabinoids being non-specific for
their targets, these compounds and their synthetic
derivatives were reported to interact with other
membrane channels. One study produced
a concentration-dependent decrease in peak current
of Kv1.2 in B82 transfected fibroblasts with complete
inhibition of current when 750nM of Anandamide
(an endocannabinoid) or 1.5 µM of Δ9-THC (a
phytocannabinoid) were introduced [16]. That
study eliminated CB1 as the method of interaction
since both cannabinoids displayed no change in
potency in the presence of SR141716A (a common
CB1 inhibitor) [16]. G-protein-coupled receptors
were also not likely to be involved since recordings
performed with nucleotide-free intracellular solu-
tions had no effect on current changes [16].
The effects of cannabinoids on ligand-gated
potassium channels were also studied. Anandamide
decreased current of ATP gated potassium channels
(KATP) during cromakalim experiments (cromaka-
lim induces outward current in follicle-enclosed
oocytes with KATP) with 8.1 µM anandamide pre-
venting current induction by 50%, with maximum
block (84 ± 7%) achieved with 100µM [23]. CB1
antagonist SR141716A and CB2 antagonist
SR144528 (both at 1µM) did not affect anandamide
inhibition of cromakalim-activated currents, again
suggesting these receptors are not required tomodify
channel currents [23]. More interestingly, ananda-
mide does not compete with the cromakalim binding
site in cromakalim-activated KATP, suggesting the
endocannabinoid is not a competitive inhibitor for
ligand-gated potassium channels [23]. Competitive
inhibition presents with altered EC50 values and
unaffected Vmax values in substrate–velocity curves,
while cromakalim EC50 values in the presence of
CBD were unaffected and Vmax values decreased
[23]. An altered Vmax with a constant EC50 classi-
fies a non-competitive inhibitor, such that the inhi-
bitor does not compete with the ligand for the active
site of the target but instead uses another site on the
protein. Again, these results suggest cannabinoids
interact with membrane channels without using
CB1 and CB2 and expands cannabinoid effects to
an additional class of membrane channels – ligand-
gated channels. This addition extends the range of
molecular targets available to cannabinoids which
suggests even more proteins could be affected and
manipulated for therapeutic use.
In addition to potassium channels, Δ9-THC
and anandamide also induce concentration-
dependent potentiation of currents mediated by
α1 homomeric and α1β1 heteromeric glycine
receptors (GlyRs) [24]. Tested in both X. laevis
oocytes and isolated ventral tegmental area neu-
rons (neurons involved in the reward pathway of
the brain) with 3µM of glycine to activate the
receptor, THC was more potent than ananda-
mide [24]. THC EC50 values for decreased
potential current were 73nM and 115nM for
heteromeric GlyRs and native GlyRs, respectively
[24]. These concentrations make the results more
physiologically relevant since they are within
pharmacological ranges that induce psychotropic
and anti-nociceptive effects in humans [24]. This
suggests large concentrations are not required to
cause a significant effect on GlyRs and promotes
the application to human use as a therapeutic
target to manipulate reward pathway problems
such as addiction since the effect was seen in
ventral tegmental area neurons. Structurally
similar to GlyRs, GABAA receptors were also
tested with both anandamide and THC yet no
significant effects were observed [24].
More specifically, CBD also affects a host of dif-
ferent membrane proteins besides Nav. Similar to
THC’s modulation of GlyRs, CBD also activates both
α1 homomeric and α1β1 heteromeric glycine recep-
tors; however, the EC50 values for direct activation
by CBD are much higher [25]. TRPV1 and other
TRP channel subfamilies were activated and desen-
sitized though patch clamp analysis on HEK293 cells
involving CBD, while TRPM8 was
inhibted [17,26,31]. In addition to Calcium currents
being affected through TRP channels, CBD also
inhibits T-Type Calcium Channels Cav3.1, Cav3.2,
and Cav3.3 in the same model system [27]. Other
CBD research reported interactions with voltage-
dependent anion-selective channel protein 1
(VDAC1), G-protein coupled receptor protein 55
(GPR55), and adenosine reuptake via Equilibrative
Nucleoside Transporter (ENT1) while potentially
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also activating A2A receptors [18,28,29]. Serotonin
receptors H5-HT1A and 5-HT2A were also targets
for CBD modulation [30].
The considerable variety of targets affected by
cannabinoids leads us to suggest there may be
a similar underlying mechanism of action for
CBD and other cannabinoids. Table 1 shows that
CBD IC50s/EC50s in particular are also consider-
ably similar between all its targets (with the excep-
tion of GlyRs). The need for further research in
this area is necessary to describe the mechanism of
CBD to understand its potential applications in
human health.
Membrane interactions
As noted above, cannabinoids interact with
a diverse group of targets including voltage-gated
channels, ligand-gated channels, and GPCRs, some
even without specificity. How do these compounds
cause these effects in such a wide range of targets?
A common feature among all these channels is
that they directly associate with the lipid mem-
brane in which they are expressed. Changes in
membrane fluidity alter conformational changes
between conducting (open) and nonconducting
(closed) states of membrane channels [32], so
changes to the membrane itself have an “indirect”
effect on channel function. One possible hypoth-
esis regarding cannabinoid interactions is that it
could alter the properties of the lipid bilayer.
When a channel sits in the bilayer, the two lipid
monolayers facilitate the movement of the channel
between different conducting states through
changes in monolayer compression and bending
[33]. The membrane’s ability to compress and
change shape is directly related to the rigidity of
the membrane which, in turn, controls channel
conformation and gating kinetics in different mem-
brane compositions [33]. Gramicidin channels can
be used to test membrane fluidity [34–36]. An
increase in fluidity permits phospholipid mono-
layers to more easily bend and increase the rate at
which two gramicidin half channels combine to
form a leak producing pore [33]. Measuring the
resultant changes in membrane resistance can be
extrapolated to assess changes in membrane fluid-
ity. Increasing bilayer rigidity by incorporating
higher concentrations of cholesterol into the bilayer
was found to shift channel activation towards more
positive potentials [33]. Using non-physiological
amphiphiles to increase fluidity in the membrane,
β-octyl-glucoside (βOG) at 5 mM and reduced
Triton X-100 (TX100) at 30 μM, reversibly inhib-
ited Nav currents (decrease peak current) [37]. βOG
and TX100 were suggested to promote the steady-
state inactivation of Nav since 2.5 mM βOG or 10
μM TX100 changed the initial voltage of activation
by −8.3 ± 1.6 mV or −9.8 ± 1.0 mV, respectively,
and the initial slope factor of activation by +2.2 ±
0.6 mV or +1.7 ± 0.3 mV, respectively [37]. These
results promote the idea that CBD could interact
with the membrane in a way to increase fluidity as
its method of protein interaction. As previously
noted, CBD inhibits current, similar to βOG and
TX100, and shifts channel activation towards nega-
tive potentials, opposite to the effect seen upon
adding cholesterol to the membrane. This suggests
Table 1. Quantitative results of Cannabidiol’s membrane pro-
tein interactions by target, cell type, and IC50 or EC50. Missing
IC50 values indicate that dose–response curves were not pro-
duced, but significant effects were demonstrated.
Target Cell type IC50 (µM)
Channels Nav1.1 HEK-293 2.0 ± 0.1 [20]
Nav1.2 HEK-293 2.9 ± 0.1 [20]
iPSCs 1.3 ± 0.1 [20]
Nav1.3 HEK-293 3.3 ± 0.1 [20]
Nav1.4 HEK-293 1.9 ± 0.1 [20]
Nav1.5 HEK-293 3.8 ± 0.2 [20]
Nav1.6 HEK-293 3.0 ± 0.1 [20]
Nav1.7 HEK-293 2.9 ± 0.1 [20]
NaChBac HEK-293 1.5 ± 0.2 [20]
Kv2.1 HEK-293 3.7 ± 0.8 [20]
TRPM8 HEK-293 0.06 ± 0.01 [26]
Cav3.1 HEK-293 0.813* [27]
Cav3.2 HEK-293 0.776* [27]














Receptors GPR55 HEK-293 0.445 ± 0.067 [29]
H5-HT1aR CHO Cells –[30]
5-HT2aR CHO Cells –[30]
Target Cell Type EC50 (µM)
Channels TRPV1 HEK-293 1.0 ± 0.1[26]
TRPV2 HEK-293 1.25 ± 0.23[26]
TRPA1 HEK-293 0.11 ± 0.05[26]
Receptors α1 homomers
GlyRs
n/a 132.4 ± 12.3[25]
α1β1 heteromers
GlyRs
n/a 144.3 ± 22.7 [25]
* Numbers calculated from pEC50 values
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that CBD increases membrane fluidity as its inter-
action mechanism.
Since CBD and other derivatives have been seen
to affect various membrane channels, and mem-
brane channels are affected by changes in mem-
brane fluidity, this raises the hypothesis that CBD
interacts with many targets by disrupting the
membrane they are embedded in. With limited
knowledge surrounding this idea, expanding CBD
research to include how this compound can alter
membrane properties would open up our under-
standing of this compound and possibly promote
its use as a potentially therapeutic compound.
Conclusion
Whereas cannabinoids initially were thought to inter-
act with their specific CB1 orCB2 receptors, a growing
body of research demonstrates that these chemical
compounds can interact with a wide range of other
targets such as sodium, potassium, and calcium chan-
nels, and serotonin and glycine receptors.
Cannabinoids interact with these targets indepen-
dently of CB1 or CB2 receptors and without specifi-
city. Other studies have reported that CBD does not
require G-proteins to activate changes in channel
function, while some studies concluded that cannabi-
noids do not need to compete for binding sites with
other ligands to make an impact.With these results in
mind, andwhile also considering the non-polar nature
of cannabinoids, one mechanism of interaction may
be that they insert into the lipid bilayer and impact
membrane fluidity. In conclusion, since changes in
membrane properties affect the function of trans-
membrane channels, cannabinoids may change chan-
nel function by their effect on lipid bilayer properties
instead of (or in addition to) directly interacting with
the channels. Although this review sought to compile
research on CBD interaction and suggest a potential
mechanism of interest, more research is needed to
determine the exact mechanism of how CBD and
other cannabinoids interact with their various mole-
cular targets. If anything, this review seeks to validate
further cannabinoid research.
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